NSE · MUKKA
Mukka Proteins Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹406 Cr with net profit ₹19 Cr — a 4.78% net margin, versus 6.04% the period before.
Shareholding
As of 2026-09-30
- Promoter73.33%
- Public24.77%
- FII1.7%
- DII0.2%
1,24,299 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.82× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Food - Processing - Indian · ranked #27 of 115 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Varun Beverages Limited | ₹1,37,431 Cr | 40.59 | 7.02 | 15.51% | 13.68% |
| Milky Mist Dairy Food Limited | ₹23,061 Cr | 183.77 | 9.96 | 27.43% | 6.54% |
| Hatsun Agro Product Ltd. | ₹21,558 Cr | 61.88 | 11.79 | 17.97% | 3.62% |
| Zydus Wellness Limited | ₹14,917 Cr | 67.36 | 2.56 | 3.98% | 4.17% |
| LT Foods Limited | ₹13,437 Cr | 20.98 | 2.97 | 13.83% | 5.5% |
| Bikaji Foods International Ltd. | ₹11,566 Cr | 44.23 | 7.2 | 16.07% | 8.57% |
| Manorama Industries Ltd. | ₹11,413 Cr | 44.18 | 9.65 | 32.97% | 17.44% |
| Godrej Agrovet Limited | ₹11,370 Cr | 24.23 | 5.59 | 23.27% | 4.27% |
| Avanti Feeds Limited | ₹9,101 Cr | 16.89 | 2.77 | 18.44% | 8.35% |
| KRBL Limited | ₹8,113 Cr | 10.7 | 1.4 | 11.16% | 12.62% |
| Mukka Proteins Limited(this company) | ₹747 Cr | 10.83 | 1.5 | 10.43% | 4.04% |
AI analysis
AI-generated · google/gemini-2.5-flashMukka Proteins Limited has a market capitalization of Rs 705 Cr, with a PE ratio of 34.06 and an EPS of 1.74. The company has a debt-to-equity ratio of 0.98. Revenue stands at Rs 1021.53 Cr, though it has experienced a growth decline of -27.1%. The profit margin is 368.9%.
Positives
- +Promoter holding is high at 73.33% as of June 30, 2026, with no pledged shares (0%).
- +The company's profit margin is substantial at 368.9%.
- +Return on equity (ROE) is 10.43% and Return on Capital Employed (ROCE) is 10.07%, indicating reasonable efficiency.
Negatives
- −Revenue growth decreased by -27.1%, indicating a significant decline in top-line performance.
- −The FII holding has decreased from 5.08% in June 2024 to 1.73% in June 2026.
- −The debt-to-equity ratio of 0.98 is close to 1, indicating a reliance on debt financing.
Financial Performance
Mukka Proteins Limited reported a revenue of Rs 1021.53 Cr. The company's revenue growth experienced a contraction of -27.1%. Quarterly revenue in March 2026 was Rs 380.6 Cr, with a net profit of Rs 20.62 Cr. The company's highest quarterly revenue in the provided data was Rs 653.5 Cr in December 2025.
Profitability & Returns
The company's profit margin is 368.9%. Return on equity (ROE) is 10.43%, while return on capital employed (ROCE) stands at 10.07%. The EPS is 1.74. For the quarter ending March 2026, net profit was Rs 20.62 Cr against an EBITDA of Rs 43.93 Cr.
Balance Sheet
Mukka Proteins Limited has a book value of Rs 16.64. The debt-to-equity ratio is 0.98. The company does not currently offer a dividend, as indicated by a dividend yield of 0%.
Ownership & Pledges
There are no shares pledged by the promoters, with promoter pledge at 0%. Overall institutional holding, including DIIs and FIIs, is 1.73% for the same period.
Regulatory & Surveillance
No specific information regarding regulatory actions or surveillance measures was provided for Mukka Proteins Limited in the supplied data.
Data as of — price: 2026-10-27 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.